dc.contributor.authorSeet, Li-Fong
dc.contributor.authorToh, Li Zhen
dc.contributor.authorChu, Stephanie
dc.contributor.authorFinger, Sharon N.
dc.contributor.authorGinhoux, Florent
dc.contributor.authorHong, Wanjin
dc.contributor.authorWong, Tina Tzee Ling
dc.date.accessioned2019-02-15T03:56:04Z
dc.date.available2019-02-15T03:56:04Z
dc.date.issued2018
dc.identifier.citationSeet, L.-F., Toh, L. Z., Chu, S., Finger, S. N., Ginhoux, F., Hong, W., & Wong, T. T. L. (2018). Bevacizumab Promotes T-Cell–Mediated Collagen Deposition in the Mouse Model of Conjunctival Scarring. Investigative Opthalmology & Visual Science, 59(3), 1682-. doi:10.1167/iovs.17-22694en_US
dc.identifier.issn0146-0404en_US
dc.identifier.urihttp://hdl.handle.net/10220/47675
dc.description.abstractPurpose: We determine the effects of bevacizumab on collagen production in a mouse model of conjunctival scarring. Methods: Experimental surgery was performed as described for the mouse model of conjunctival scarring, and bevacizumab was introduced by conjunctival injection. The capacity of bevacizumab to recognize conjunctival VEGF-A was determined by ELISA. Col1a1 was measured by real-time PCR and immunoblotting. T cells and collagen were visualized by immunofluorescence and picrosirius red staining of bleb cryosections. Conjunctival CD4+ or CD8a+ T cells were counted by flow cytometry. Mouse splenic T cells were cultured with bevacizumab/IgG and their numbers, cell cycle, and collagen production were measured using a cell counter, flow cytometry, and sircol soluble collagen assay, respectively. Reconstitution experiments in severe combined immunodeficiency (SCID) mice were performed by injection of freshly isolated T cells on day 2 postoperatively. Results: Bevacizumab recognized approximately 20% of endogenous murine VEGF-A. Injection of bevacizumab raised Col1a1 expression in the blebs at mRNA and protein levels. Bevacizumab did not induce collagen in conjunctival fibroblasts, but increased CD4+ and CD8a+ cell numbers as well as collagen production by these cells. Collagen appeared to accumulate in the vicinity of T cells in the bevacizumab-treated blebs. While SCID blebs did not show elevated collagen levels, reconstitution with CD4+ or CD8a+ cells resulted in increased Col1a1 expression at mRNA and protein levels. Conclusions: Bevacizumab increased collagen production in the mouse model of conjunctival scarring. This collagen induction was mediated by T cells that were also stimulated by bevacizumab to increase in numbers.en_US
dc.description.sponsorshipNRF (Natl Research Foundation, S’pore)en_US
dc.description.sponsorshipNMRC (Natl Medical Research Council, S’pore)en_US
dc.format.extent11 p.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesInvestigative Opthalmology & Visual Scienceen_US
dc.rights© 2018 The Authors. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.en_US
dc.subjectDRNTU::Engineering::Materialsen_US
dc.subjectBevacizumaben_US
dc.subjectCollagenen_US
dc.titleBevacizumab promotes T-cell–mediated collagen deposition in the mouse model of conjunctival scarringen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Materials Science and Engineeringen_US
dc.identifier.doihttp://dx.doi.org/10.1167/iovs.17-22694
dc.description.versionPublished versionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record